Background
Accurate staging of patients with prostate cancer (PCa) is important for therapeutic decision-making. Relapse after surgery or radiotherapy of curative intent is not uncommon and, in part, represents a failure of staging with current diagnostic imaging techniques to detect disease spread. Prostate-specific membrane antigen (PSMA) positronemission tomography (PET)/computed tomography (CT) is a new whole-body scanning technique that enables visualization of PCa with high contrast. The hypotheses of this study are that: (i) PSMA-PET/CT has improved diagnostic performance compared with conventional imaging; (ii) PSMA-PET/CT should be used as a first-line diagnostic test for staging; (iii) the improved diagnostic performance of PSMA-PET/CT will result in significant management impact; and (iv) there are economic benefits if PSMA-PET/CT is incorporated into the management algorithm.
Objectives and Methods
The proPSMA trial is a prospective, multicentre study in which patients with untreated high-risk PCa will be randomized to gallium-68-PSMA-11 PET/CT or conventional imaging, consisting of CT of the abdomen/pelvis and bone scintigraphy with single-photon emission CT/CT. Patients eligible for inclusion are those with newly diagnosed PCa with select high-risk features, defined as International Society of Urological Pathology grade group ≥3 (primary Gleason grade 4, or any Gleason grade 5), prostate-specific antigen level ≥20 ng/mL or clinical stage ≥T3. Patients with negative, equivocal or oligometastatic disease on first line-imaging will cross over to receive the other imaging arm. The primary objective is to compare the accuracy of PSMA-PET/CT with that of conventional imaging for detecting nodal or distant metastatic disease. Histopathological, imaging and clinical follow-up at 6 months will define the primary endpoint according to a predefined scoring system. Secondary objectives include comparing management impact, the number of equivocal studies, the incremental value of second-line imaging in patients who cross over, the cost of each imaging strategy, radiation exposure, inter-observer agreement and safety of PSMA-PET/CT. Longer-term followup will also assess the prognostic value of a negative PSMA-PET/CT.
Introduction
Prostate cancer (PCa) is the most commonly diagnosed cancer in Australia, representing a third of all cancers in men, and accounting for~20 000 new cases diagnosed per year. PCa was the second leading cause of cancer deaths in Australian men in 2011, and the fourth leading cause of all deaths [1] . Defining the extent of PCa with accurate imaging is of utmost importance for therapeutic decision-making. Current diagnostic tools are suboptimal for the staging of patients with metastatic disease. Structural imaging techniques such as CT and MRI have limited sensitivity and specificity to detect small-volume metastatic disease, while a whole-body bone scan can miss early bone marrow metastases. Despite these limitations, CT and whole-body bone scans are widely accepted as standard first-line diagnostic imaging evaluation for staging patients with localized PCa [2] . More recently, positron-emission tomography (PET) imaging with 11 Ccholine, 18 F-fluorocholine or 18 F-fluoride bone PET/CT have demonstrated superior accuracy [3] [4] [5] [6] , but these techniques remain limited by their inherent non-specificity [7] .
Prostate-specific membrane antigen (PSMA) is a cell surface transmembrane glycoprotein expressed by the majority of PCa cells and has been established as a target for imaging and also treatment of PCa. PSMA imaging was initially undertaken using the radiolabelled antibody capromabpendetide (ProstaScintâ). This was approved by the US Food and Drug Administration but the radiotracer targeted the intracellular epitope of PSMA and, combined with the low resolution of single-photon emission CT (SPECT) imaging, the technique failed to provide sufficient additional value compared with conventional imaging [8, 9] . Newer-generation small molecular ligands that target PSMA have renewed interest in using PSMA-targeted imaging of PCa. The most widely adopted to date is gallium-68 (   68   Ga)-PSMA-11, also  known as   68   Ga-HBED-CC or   68 Ga-HBED-PSMA, developed by the Division of Radiopharmaceutical Chemistry at the DKFZ Heidelberg [10, 11] . This is a radioconjugate composed of a small-molecule PSMA targeting ligand conjugated to the radioisotope 68 Ga, which is a positron-emitting isotope that is produced using a small generator device with capacity to have wide clinical availability at relatively low cost.
68
Ga-PSMA-11 binds with affinity to the extracellular domain of PSMA, with rapid uptake and plasma clearance. PET imaging technology also provides superior resolution compared with conventional nuclear medicine imaging [12] .
The data in the literature to date are primarily focused on 68 Ga-PSMA-PET/CT (PSMA-PET/CT) for localization of PCa in patients with biochemical recurrence [13] [14] [15] [16] [17] [18] [19] [20] [21] , although data on primary staging are also emerging [17, 22, 23] , and both have been the subject of a recent meta-analysis [24] . The utility of PSMA PET/CT to identify lymph node involvement in the primary staging stetting is also encouraging, even for sub-centimetre lymph nodes [22, 25] . The use of radio-guided surgery for lymph nodes identified by PSMA PET/CT is also under investigation [26, 27] . A particular area of note is that of disease localization in patients with biochemical recurrence after radical prostatectomy, who are being considered for salvage radiotherapy, a group of patients in whom conventional imaging has particularly poor sensitivity. Van Leeuwen et al. [28] reported their experience of PSMA PET/CT in 70 such patients (median PSA 0.2 ng/mL; no patients with PSA >1.0 ng/mL), and observed positive scans in >50% of patients. Of particular note, 28.6% of patients had positive scans outside the prostate bed, with significant management impact.
Whilst these data clearly demonstrate the utility of PSMA-PET/CT [29] , they were mostly obtained from retrospective single-centre studies, and do not directly compare PSMA-PET/CT with conventional imaging or address important issues such as the impact of this new imaging test on patient management, patient outcomes or resource use. In particular, the use of PSMA-PET/CT for primary staging is of critical importance as more accurate staging will potentially have high patient impact by selecting more appropriate management for an individual patient through better selection and planning of definitive treatment strategies. Current recommendations for imaging patients with newly diagnosed PCa vary in different international guidelines [2] . Generally, imaging is only recommended in patients at high risk as the rate of false-positive results may outnumber truepositive results if the likelihood of metastatic disease is very low. If the yield of imaging is low, there are also significant health economic implications. This study will incorporate the new five-tier International Society for Urological Pathology (ISUP) grade group system, which has been shown to provide superior prognostic stratification compared with the traditional Gleason score [35] [36] [37] .
proPSMA Clinical Trial Overview
This is a multicentre, prospective, randomized study that compares PSMA-PET/CT with conventional imaging for staging of patients with high-risk localized PCa. The goal of this trial is to provide robust high-level data that will establish whether PSMA-PET/CT should replace conventional imaging in the assessment of such patients, or whether it should be used to provide incremental diagnostic information in selected cases. The hypotheses of this study are that: (i) PSMA-PET/CT has improved diagnostic accuracy compared with conventional imaging; (ii) PSMA-PET/CT should be 784 © 2018 The Authors BJU International © 2018 BJU International used as a first-line diagnostic test for staging high-risk localized PCa; (iii) the improved diagnostic accuracy of PSMA-PET/CT will result in significant management impact; and (iv) there are economic benefits if PSMA-PET/CT is incorporated into the management algorithm.
The primary objective of this study is to compare the diagnostic accuracy of PSMA-PET/CT with that of conventional imaging for detecting nodal or distant metastatic disease. The secondary objectives are as follows:
1 to compare the first-line management impact of PSMA-PET/CT with that of conventional imaging; 2 to compare the number of equivocal study results using PSMA-PET/CT with the number using conventional imaging; 3 to assess the incremental accuracy of PSMA-PET/CT or conventional imaging as a second-line imaging technique by their ability to detect additional metastases in a subset of patients who cross over and undergo both tests; 4 to assess the incremental management impact of PSMA-PET/CT or conventional imaging as a second-line imaging technique in the subset of patients who cross over and undergo both tests; 5 to evaluate the prognostic value of PSMA-PET/CT with regard to disease-free status (2 years from accrual of the last patient); 6 to compare the cost of each imaging staging strategy; 7 to compare patient radiation exposure between imaging strategies; 8 to assess inter-reporter agreement of PSMA-PET/CT by comparing blinded central imaging laboratory interpretations to on-site clinical care interpretations; 9 To report the acute adverse events for PSMA-PET/CT.
A tertiary objective is to investigate the diagnostic accuracy of whole-body MRI compared with PSMA PET/CT in a nonrandomized exploratory endpoint.
Patients and Methods
We aim to evaluate the role of PSMA-PET/CT in a patient population with a significant risk of metastatic disease, but a relatively low pre-test likelihood of positive conventional imaging results. This will be defined by ISUP grade group ≥3 (primary Gleason grade 4, or any Gleason grade 5), PSA ≥20 ng/mL or clinical stage ≥T3. A total of 300 patients will be recruited in up to 10 centres. Follow-up for the study will stop 2 years after randomization of the last patient. The inclusion and exclusion criteria are listed in Table 1 . The trial schema is outlined in Fig. 1 , and an abbreviated Schedule of Events in Table 2 .
First-Line Diagnostic Imaging
The participant will undergo first-line diagnostic imaging within 21 days of randomization.
Patients in the experimental arm will undergo PET/CT after injection of Patients in the control arm will undergo contrast-enhanced CT (abdomen and pelvis) and whole-body bone scan with SPECT/CT, encompassing thorax, abdomen and pelvis.
Second-Line Diagnostic Imaging
Patients will cross over to the other arm (second-line diagnostic imaging) unless ≥3 sites of unequivocal distant metastases are demonstrated. After second-line imaging, at the discretion of the treating doctor as per routine clinical care, additional confirmatory studies may be performed to further evaluate the Table 1 Study inclusion and exclusion criteria.
Inclusion criteria 1 Untreated, biopsy-proven adenocarcinoma of the prostate 2 Curative-intent treatment with radical prostatectomy or radiotherapy being considered 3 PCa with high-risk features including at least one of the following:
○ PSA ≥20.0 ng/mL <12 weeks before randomization ○ Gleason grade group 3, 4 or 5 ○ Clinical stage ≥T3 4 Age ≥18 years 5 Written informed consent provided for participation in the trial 6 In the opinion of investigator, willing and able to comply with required study procedures Exclusion criteria 1 Any prior therapy for PCa 2 Imaging undergone for the primary purpose of staging pelvic nodal or distant metastatic disease of PCa (MRI performed for primary purpose of assessing Tstage or to guide biopsy is acceptable) <8 weeks before randomization 3 History of other active malignancy within the last 2 years, with exception of nonmelanoma skin cancer or melanoma in situ 4 PCa with significant sarcomatoid or spindle cell or neuroendocrine small cell components 5 Significant intercurrent morbidity that, in the judgement of the investigator, would limit compliance with study protocols PCa, prostate cancer.
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Six-Month Follow-Up Imaging
Repeat imaging as per randomized arm with crossover will be performed at 6 months (AE30 days) after randomization in patients with (i) initial staging of N1 or M1 or (ii) biochemical or clinical suspicion of residual/recurrent disease for patients with initial stage N0 M0. Temporal changes identified on imaging will assist in defining the primary endpoint. 
PSMA PET/CT Quality Control
The production, quality control and release of 68 Ga-PSMA must meet minimum study specifications. The production method may be automated or manual and must pass full quality control with a minimum of three consecutive validation runs before enrolling patients ( Table 3) . The minimum quality control requirements for each 68 Ga-PSMA-11 synthesis prior to release for patient administration will consist of: (i) appearance (visual inspection); (ii) label inspection; (iii) pH; (iv) radiochemical identity (half-life); (v) radiochemical purity (high-performance liquid chromatography and thin-layer chromatography); and (vi) measurement of total radioactivity at reference time (by dose calibrator).
PET/CT Quality Assurance
Before beginning enrolment, all PET imaging sites will be certified by an independent review of equipment provided by the Australasian Radiopharmaceutical Trials Network (ARTnet). This will be carried our using the ARTnet phantom (NEMA NU2 IEC Body Phantom) filled with 68 Ga and performing PET acquisition with clinical protocols. The DICOM data will be analysed by the ARTnet core laboratory to ensure minimum specifications are met. By analysing the average standardized uptake value against the injected activity, the process will also provide validation of the dose calibrator for 68 Ga.
During the study, further quality assurance will be performed by a central core imaging laboratory (CIL). The PSMA PET/ CT images in DICOM format for first-line and second-line imaging will be sent to the CIL in an anonymized format. Two experienced readers will review the study at the CIL, with any disagreement resolved by consensus. The results from the CIL will be sent back to the local reader within 3 business days of the scan acquisition. Any discrepancy of the scan findings between the local reader and central review will be resolved by discussion in order to reach a consensus. If a consensus cannot be reached, this will be recorded, and the patient will be managed according to results of the local reader.
PET/CT Acquisition PSMA PET/CT will be performed after administration of 1.8-2.2 MBq 68 Ga-PSMA-11 per kg body weight, subject to Ga-PSMA-11 administration. The patient should be well hydrated and void immediately before commencement of the scan. The CT will be performed without contrast. PET image acquisition should be from pelvis towards head, with a minimum bed step acquisition time of 120 s.
Magnetic Resonance Imaging
A subset of up to 50 patients will participate in the exploratory non-randomized MRI endpoint. These patients will undergo whole-body MRI using a standardized comprehensive protocol targeted for evaluation of pelvic nodal and distant metastatic disease. MRI will be performed after first-and second-line evaluation, and clinical reports will not be issued. MRI scans for research purposes will be centrally read to ascertain reporter agreement with local reading. A total of 50 whole-body MRI procedures will be performed.
Clinical Management
Clinical management of patients within this study is at the discretion of individual clinicians working within a multidisciplinary framework. The study protocol does not determine how patients are managed; however, the management impact of each imaging technique is recorded by the treating clinician after each scan. As these patients are being considered for localized treatment at the time of inclusion, it is expected that the majority of patients within the study will proceed to radical prostatectomy, with or without lymph node dissection, or radiotherapy (external beam or high-dose rate brachytherapy). Pathological findings at surgery will be compared with imaging.
Sample Size and Power Calculation for the Primary Endpoint
Sample size was estimated to test the hypothesis that PSMA PET/CT achieves an area under the curve (AUC) at least 10% better (absolute) than conventional imaging. Simulation was used to estimate that a sample size of 180 (90 patients per arm) will achieve a power of 0.8 using the following pragmatic assumptions: (i) conventional imaging has a true underlying AUC of 0.65, consisting of a sensitivity of 0.65 and a specificity of 0.65; (ii) PSMA-PET/CT has a true underlying AUC of 0.9, consisting of a sensitivity of 0.9 and a specificity of 0.9; (iii) the proportion of cases (as opposed to controls) is 40%; and (iv) a two-sided type I error of 10%. In January 2018, the sample size was revised based on a proportion of cases of 25%. With this change, a sample size of 270 (135 patients per arm) will achieve a power of 0.85.
To allow for a patient drop-out rate of up to 10%, 300 patients will be accrued to the study.
Results
The study endpoints are summarized in Table 4 .
Accuracy
The diagnostic accuracy of PSMA-PET/CT and conventional imaging for determining the presence or absence of pelvic nodal or distant metastases will be evaluated as the primary endpoint. To define accuracy, diagnostic findings will be compared with the ground truth, which will be established using all data available to the 6-month follow-up time point (AE30 days). Where feasible, biopsy confirmation of disease is strongly encouraged. Criteria adapted from a prior RCT designed to assess 18 F-PET in PCa (NCT00882609) were modified. Cases will be considered positive by ground truth if they satisfy at least one hard criterion or at least three soft criteria amongst the criteria as listed in Table 5 . These criteria will be applied for pelvic nodal (N) and distant metastatic (M) disease.
Accuracy will be assessed by the area under the receiveroperating characteristic curve (the AUC). The receiveroperating characteristic curve for a diagnostic instrument is the curve of sensitivity against 1 -specificity, as the threshold for rating an assessment as 'positive' changes. When the diagnostic instrument produces a dichotomous (true/false) decision, as is the case in this study, the AUC is simply equal to the mean of the sensitivity and specificity. For the purposes of estimating sensitivity, specificity and AUC, lesions rated as equivocal will be considered negative for metastatic disease. The primary analysis will be a patient-level analysis with any pelvic nodal (N) or distant metastatic (M) disease considered positive. We will report the difference in AUC between the arms, its 95% CI, and the P value for the null hypothesis that the AUC for the PSMA arm is 10% greater (absolutely) than the AUC in the conventional imaging arm.
Management Impact
The treating clinician will record the intended management plan at baseline, following first-and second-line imaging. Management impact will be classified as shown in Table 6 . The proportion of patients requiring a change of management will be compared between arms using an exact test for comparing two independent binary variables (either Fisher's exact test or Barnard's test).
Equivocal Studies
An equivocal imaging finding may result in further investigations, delays in undertaking definitive intervention and/or increased patient anxiety. For conventional imaging, the combined findings of both CT and bone scan are considered. In patients with multiple lesions, the finding is only considered to be an equivocal study if there are no positive sites; for example, if there are two bone metastases, one classified as positive for metastatic disease and another classified as equivocal, the study is not deemed equivocal. The frequency of equivocal findings for pelvic nodal and distant metastases will be reported separately.
Incremental Accuracy of Second-Line Imaging
The incremental accuracy of second-line diagnostic imaging is a measure of its ability to uncover disease that was not diagnosed by a first-line diagnostic imaging technique. All patients who crossed over will be included in the assessment of this endpoint. For each arm considered separately, the proportion of patients with M0 disease who were upstaged to M1 by second-line imaging (with any number of metastases) will be estimated, together with its 95% CI, using an exact method. In addition, the proportion of N0 patients who were upstaged to N1 by second-line imaging will be estimated using the same method. Amongst M1 patients with oligometastatic disease, the extent of upstaging elicited by second-line imaging will be separately estimated.
Incremental Management Impact of Second-Line Imaging
The incremental management impact of a second-line diagnostic imaging is a measure of its ability to result in a management change compared with the post first-line management plan. Amongst patients who crossed over to second-line imaging, the proportion of patients experiencing a change in management as a result of second-line imaging will be estimated, together with its 95% CI, estimated using an exact method. Table 5 Ground truth criteria using all information available up until 6 months post randomization (a minimum of one hard criteria or three soft criteria must be met). • Unequivocal persistence of positive finding present on the baseline scan on repeat imaging at 6 months, in setting of PSA >0.2 ng/mL at least 3 weeks after prostatectomy 
Prognostic Value
The prognostic value of PSMA PET/CT is the ability of a negative PSMA PET/CT for distant metastatic disease at baseline (first-or second-line diagnostic imaging) to predict time until clinical treatment failure. Results will be stratified by staging of baseline PSMA PET/CT into two groups: N0 M0 and N1 M0. Each of the following three kinds of clinical treatment failure will be considered separately and collectively.
Biochemical Failure
For patients treated with radiotherapy, biochemical failure will be defined as a rise of ≥2 ng/mL above the nadir PSA >6 weeks after completion of radiotherapy. For patients treated with surgery, this will be defined as a PSA of >0.2 ng/ mL and rising on at least two consecutive measures at least 3 weeks apart after surgical therapy.
Regional or Distant Metastatic Disease
Regional or distant metastatic disease will be defined by biopsy confirming recurrent prostate carcinoma or unequivocal development of abnormalities on imaging.
Salvage Therapy
Salvage therapy will be defined by receipt of additional PCa therapy after initial prostate surgery or radiotherapy.
Kaplan-Meier curves will be plotted for time until the first of (i) biochemical failure, (ii) metastatic disease or (iii) salvage therapy.
Health Economic Analysis

Service Delivery
Costs for the delivery of diagnostic imaging services will consider the equipment, personnel and time resources involved for the development and preparation of scanning services. For PSMA-PET/CT, consideration will be given to whether production occurs at the site. For on-site production, the time required by personnel for production and quality assurance of a batch of 68 Ga-PSMA-11 will be required. The consumable and equipment items required including cartridges, kits, chemicals or reagents, disposable equipment, gallium generator, automated synthesis unit and a highperformance liquid chromatography system will be recorded.
Cost per activity required for diagnostic imaging preparation will be estimated by applying prices to each resource type used to deliver imaging services, and aggregating over the specific components of diagnostic imaging preparation. This will compare PSMA PET/CT with the conventional imaging (cost of both CT and bone scanning). Resources will be valued for costing purposes using publicly available sources, such as those published online via the Medicare Benefits Schedule for publicly funded services in Australia.
Patient Impact
The two modes of diagnostic imaging administration are anticipated to have different impacts on patient time and activity. For example, PSMA PET is administered over 1 day and requires~1 h between the administration of the radiotracer and initiation of PET. Patients undergoing CT and bone scans will have two scans (often on separate days), with the bone scan requiring up to 4 h between administration of radiotracer and initiation of the scan. To assess the impact on patient time and activity associated with complying with diagnostic imaging, the patient waiting time (assessed as the difference between time of the radiotracer administration and the time the scan commenced) and duration of the procedure (difference between the time the patient commences the scan and the time the scan is completed and patient leaves) will be assessed.
Radiation Exposure to Patients
Cumulative radiation exposure will be defined as the sum of the effective doses from first-line diagnostic imaging, secondline diagnostic imaging and any confirmatory diagnostic imaging. The radiation dose from CT examinations including the CT component of PET/CT and SPECT/CT will be calculated from the dose-length product using conversion factors [38] , with the results reported in millisieverts. When the dose-length product is not available, the average radiation dose on the basis of trial data will be used. For nuclear medicine imaging, the effective dose will be calculated from the administered activity of radio-isotope injected. For other types of imaging performed for confirmatory imaging, the effective dose will be estimated based on the type of examination performed. Radiation exposure will be compared between the randomized groups with the use of Student's unpaired t-test if its assumption of normality within each arm is not breached. Otherwise, the Wilcoxon rank-sum test will be used.
Reporter Agreement
All PSMA-PET/CT performed as first-or second-line imaging will be centrally read. Levels of agreement between the central rater and the local raters for pelvic nodal and distant disease will be estimated using the stratified Cohen's weighted j [39] , with stratification by site.
Adverse Events
Acute adverse events associated with PSMA-PET/CT will be recorded, defined as those experienced by the patient at the 790 © 2018 The Authors BJU International © 2018 BJU International time of radiotracer administration and during the 2 h after injection. Any toxicity will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 and its relationship to the diagnostic imaging will be described as unrelated, unlikely, possible, probable or definite. The worst grade of each toxicity type for each patient within the toxicity assessment window will be tabulated.
Discussion
Although there has been a surge in publications regarding the use of 68 Ga-PSMA-PET/CT in PCa [40] , most of these have been retrospective, single-centre studies. Furthermore, the majority of publications to date have focused on biochemical recurrence, with less evidence for the role of PSMA PET/CT in primary staging. Despite these limitations, results from the literature suggest superior sensitivity and specificity of 68 Ga-PSMA-PET/CT over other techniques, as illustrated in a metaanalysis by Perera et al. [24] . Conducting a well-designed, prospective, multicentre randomized clinical trial will provide robust data on the utility of PSMA PET compared with conventional imaging in the primary staging setting of patients with high-risk localized PCa. In the short to medium term, the improved detection of metastatic disease in the primary staging of high-risk PCa is likely to have high impact on patient management, by directing more appropriate treatment.
The cost of diagnostic imaging is increasingly recognized as a major component of health expenditure. Diagnostic imaging accounts for~15% of Australia's government-funded system (Medicare) outlay, with estimated costs of $3.1 bn per annum [41] . The use of diagnostic imaging is showing rapid growth worldwide. By incorporating a health economic analysis into the clinical trial, this study should inform healthcare providers of the costs of PSMA-PET/CT compared with conventional imaging in the management of PCa. Given the high incidence of PCa in Australia, this may have significant implications for the long term.
The proPSMA study has commenced, with all 11 participating sites now activated and actively recruiting. The first patient was randomized in March 2017 and recruitment is proceeding on target. As part of multicentre site validation, it was identified in 68 Ga phantom validation studies that 10 of the 14 PET systems underestimated the standardized uptake value by 15% on average. We identified an incorrect factory-shipped dose calibrator setting as the cause. This was corrected at each site prior to site activation [42] . This experience emphases that prequalifying site assessment testing of the entire chain of measurements and calibration required for PET imaging is an important aspect of quality assurance.
The proPSMA randomized study design is innovative because it assesses the impact of PSMA-PET/CT as either a first-or second-line investigation. This will enable us to establish whether PSMA-PET/CT should replace conventional imaging in the primary staging of high risk disease or whether it should be used to provide incremental diagnostic information in selected cases. The integration of the trial into real-world practice with a practical clinical endpoint [43] will contribute significantly to the global literature and may provide a strong case for changing the conventional investigation paradigm of PCa.
